Keith D. Eaton, MD, PhD

Why did you become an oncologist?

I was always drawn toward the sciences, particularly physics and math. But in graduate school, I began to feel like something was missing; the more I pursued these interests, the more I felt removed from people. Then I met my wife, who was in medical school at the time. Through her, I discovered that a career in medicine would be scientifically challenging while also providing that missing human element, so I switched gears and decided to become a physician. What I like about being an oncologist is that I get to treat the whole person, not just their illness. I’m interested in how someone is coping, what their priorities are and how I can help them lead a healthy, fulfilling life despite a cancer diagnosis.

Do you have a personal connection with cancer?

In 2012, I was diagnosed with leukemia and was given less than a 5 percent chance of survival. Kind of like Harry Potter — I’m the boy who lived. As a survivor, I never lose sight of how fortunate I am to support others as they face the challenges of cancer diagnosis and treatment. I consider patient education to be one of the most important aspects of my work because it empowers you to make informed decisions and participate fully in your care. I’m known as kind, patient, a good listener and an open, compassionate communicator. I’m committed to answering all your questions honestly and really getting to know you.

Provider Background

Area of Clinical Practice
Head and neck cancers, thoracic cancers

Lung Cancer, Head and Neck Cancer, Cancer of Unknown Primary
I provide care for patients with cancers of the lung, thyroid, head and neck, as well as those diagnosed with cancer of unknown primary (CUP), a rare disease in which the origin of malignant cells found in the body is not known. In addition to providing clinical care, I serve as the medical director for quality, safety and value at Fred Hutch. In this role, I focus on improving cancer care at a systems level, from the way we communicate with patients to the way we deliver care at the end of life, among other areas. From a research perspective, I lead clinical trials investigating novel drug therapies for lung cancer. I also collaborate with colleagues seeking to better understand cancer biology and to develop more targeted treatments.